Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696072 · ClinicalTrials.gov registry record · Phase 2
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00696072 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 120 participants.
The verdict
NCT00696072, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone
Interventions
- DRUG Letrozole
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2008-08 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00696072
The ClinicalTrials.gov registry entry for NCT00696072 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Letrozole is the first listed.
NCT00696072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00696072 about?
NCT00696072 is a clinical study titled "Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic". The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone
What is the current status of trial NCT00696072?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2008-08. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00696072?
The interventions under investigation include: Letrozole (DRUG), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00696072?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.